Prognosis Relevance of Serum Cytokines in Pancreatic Cancer
MetadatosMostrar el registro completo del ítem
AutorTorres, Carolina; Linares Gil, Ana; Alejandre Pérez, María José; Palomino Morales, Rogelio; Caba Pérez, Octavio; Prados, José; Aránega Jiménez, Antonia; Delgado Pérez, Juan Ramón; Irigoyen, Antonio; Martínez-Galán, Joaquina; Ortuño, Francisco M.; Rojas Ruiz, Ignacio; Perales Romero, Sonia
Hindawi Publishing Corporation
Serum cytokinesPancreatic cancerChemotherapyMarkersPancreatic ductal adenocarcinoma
Torres, C.; et al. Prognosis Relevance of Serum Cytokines in Pancreatic Cancer. Biomed Research International, 2015: 518284 (2015). [http://hdl.handle.net/10481/37314]
PatrocinadorThe study was fully supported by ROCHE FARMA S.A (ref. H/OH-TAR-10/131 and ref. H/OH-TRR-08/59) and Instituto de Salud Carlos III (ISCIII) (Clinical trial ref. EC08/00009), and the Government of Andalusia Project P12-TIC-2082.
The overall survival of patients with pancreatic ductal adenocarcinoma is extremely low. Although gemcitabine is the standard used chemotherapy for this disease, clinical outcomes do not reflect significant improvements, not even when combined with adjuvant treatments. There is an urgent need for prognosis markers to be found. The aim of this study was to analyze the potential value of serum cytokines to find a profile that can predict the clinical outcome in patients with pancreatic cancer and to establish a practical prognosis index that significantly predicts patients’ outcomes. We have conducted an extensive analysis of serum prognosis biomarkers using an antibody array comprising 507 human cytokines. Overall survival was estimated using the Kaplan-Meier method. Univariate and multivariate Cox’s proportional hazard models were used to analyze prognosis factors. To determine the extent that survival could be predicted based on this index, we used the leave-one-out cross-validation model. The multivariate model showed a better performance and it could represent a novel panel of serum cytokines that correlates to poor prognosis in pancreatic cancer. B7-1/CD80, EG-VEGF/PK1, IL-29, NRG1-beta1/HRG1-beta1, and PD-ECGF expressions portend a poor prognosis for patients with pancreatic cancer and these cytokines could represent novel therapeutic targets for this disease.